{
    "organizations": [],
    "uuid": "4cca3412e16a9ac1ecc2f3d176cfb2b440df7460",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hemogenyx-pharmaceuticals-says-lea/brief-hemogenyx-pharmaceuticals-says-lead-candidate-shown-to-be-effective-in-treatment-of-leukemia-idUSASM000JQF",
    "ord_in_thread": 0,
    "title": "BRIEF-Hemogenyx Pharmaceuticals Says Lead Candidate Shown To Be Effective In Treatment Of Leukemia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Hemogenyx Pharmaceuticals Plc:\n* HEMOGENYX PHARMA PLC - STMNT RE SHARE PRICE MOVEMENT\n* HEMOGENYX PHARMACEUTICALS - ‍CONFIRMS IT HAS FILED A PROVISIONAL PATENT APPLICATION RELATING TO COMPANY‘S DEVELOPMENT OF A NEW TYPE OF HUMANISED MICE\n* HEMOGENYX PHARMA- ‍FIRST DATA RESULTS HAVE SHOWN CDX BI-SPECIFIC ANTIBODIES ARE CAPABLE OF ATTACKING AND ELIMINATING BLOOD CANCER ACUTE MYELOGENOUS LEUKEMIA IN VITRO​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-26T22:22:00.000+02:00",
    "crawled": "2018-02-27T14:46:46.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "hemogenyx",
        "pharmaceutical",
        "plc",
        "hemogenyx",
        "pharma",
        "plc",
        "stmnt",
        "share",
        "price",
        "movement",
        "hemogenyx",
        "pharmaceutical",
        "filed",
        "provisional",
        "patent",
        "application",
        "relating",
        "company",
        "development",
        "new",
        "type",
        "humanised",
        "mouse",
        "hemogenyx",
        "data",
        "result",
        "shown",
        "cdx",
        "antibody",
        "capable",
        "attacking",
        "eliminating",
        "blood",
        "cancer",
        "acute",
        "myelogenous",
        "leukemia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}